Bristol Myers Squibb (BMY) is seeing renewed demand at the 20-day exponential moving average following a pullback. The stock remains in a strong uptrend, defined by higher highs and higher lows, and continues to trade above its key moving averages, which are positively aligned—reinforcing bullish conviction.
Bristol Myers Squibb Co. is a $111.84 billion market-capitalization biopharmaceutical company engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of innovative therapies. Its portfolio includes small-molecule drugs, biologics derived from biological processes, and advanced chimeric antigen receptor T-cell (CAR-T) therapies.
Fundamentally, BMY is considered a wide economic-moat company. It has delivered revenue growth in four of the past five quarters and EPS growth in two of the last five quarters. Over the past four quarters, return on equity has averaged around 30%, return on invested capital approximately 8%, and net margins about 17%. From a balance-sheet perspective, the company maintains a current ratio of 1.27x, while leverage remains elevated with a debt-to-equity ratio of 2.75x.
BMY
Bristol Myers Squibb Co. is a $111.84 billion market-capitalization biopharmaceutical company engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of innovative therapies. Its portfolio includes small-molecule drugs, biologics derived from biological processes, and advanced chimeric antigen receptor T-cell (CAR-T) therapies.
Fundamentally, BMY is considered a wide economic-moat company. It has delivered revenue growth in four of the past five quarters and EPS growth in two of the last five quarters. Over the past four quarters, return on equity has averaged around 30%, return on invested capital approximately 8%, and net margins about 17%. From a balance-sheet perspective, the company maintains a current ratio of 1.27x, while leverage remains elevated with a debt-to-equity ratio of 2.75x.
BMY 
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.